JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
15/12/23 - 17:38
Diasorin Board of Directors approves 2024-2027 Business Plan (294.02 KB)
06/11/23 - 15:44
Diasorin and Gilead Sciences collaborate to develop a Fully Automated Diagnostic Assay for Hepatitis Delta Virus on Diasorin’s LIAISON XL® for the U.S. Market (506.97 KB)
03/11/23 - 15:51
Third Quarter results confirm guidance for Fiscal Year 2023 (822.89 KB)
24/10/23 - 15:03
Diasorin unveils its new Corporate identity and launches the new Group website: www.diasorin.com (574.08 KB)
27/07/23 - 14:27
Update 2023 Annual Calendar of Corporate Events (104.1 KB)
27/07/23 - 13:18
Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed (598.06 KB)
17/07/23 - 7:03
DiaSorin launches the LIAISON® Legionella Urinary Ag assay in all countries accepting the CE Mark to improve diagnosis of legionnaires’ disease (510.4 KB)
03/07/23 - 11:48
Suspension of the effectiveness of the disqualifying accessory administrative sanction imposed by CONSOB to the Chief Executive Officer Mr. Carlo Rosa (102.52 KB)
13/06/23 - 15:18
DiaSorin launches the LIAISON® B·R·A·H·M·S MR-proADM™ assay in all countries accepting the CE Mark (578.05 KB)
07/06/23 - 14:40
Communication of total amount of voting rights (7 June 2023) (141.14 KB)
05/06/23 - 21:58
Administrative sanctions imposed by CONSOB in connection with the alleged breach to disclose obligations relating to inside information. Action for annulment. (107.91 KB)
26/05/23 - 7:10
DIASORIN CONSOLIDATES STRATEGIC PARTNERSHIP WITH MEMED BY SIGNING AN AGREEMENT TO DISTRIBUTE MEMED BV® TEST FOR THE ITALIAN MARKET ON THE MEMED KEY® POINT-OF-NEED PLATFORM (159.38 KB)
09/05/23 - 11:56
Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023 (675.79 KB)
28/04/23 - 12:52
Shareholders' Meeting 2023 (373.48 KB)
27/03/23 - 15:52
Update 2023 Annual Calendar of Corporate Events (483.89 KB)
27/03/23 - 14:38
Dividend coupon date correction (493.46 KB)
27/03/23 - 13:35
REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE (334.51 KB)
17/03/23 - 22:05
DiaSorin Simplexa COVID Flu assay received U.S. FDA 510(K) clearance (155.02 KB)
28/02/23 - 16:06
Sale of Flow Cytometry and Imaging business from DiaSorin to Cytek® Biosciences completed (130.89 KB)
13/02/23 - 22:03
CYTEK BIOSCIENCES TO ACQUIRE FLOW CYTOMETRY AND IMAGING BUSINESS FROM DIASORIN (165.22 KB)
07/02/23 - 12:01
Update 2023 Annual Calendar of Corporate Events (288.3 KB)
29/12/20 - 18:22
DiaSorin has received BARDA Funding in support of submitting the SIMPLEXA COVID-19 Direct Kit for 510(k) clearance (400.67 KB)
17/12/20 - 17:57
DiaSorin - Policlinico San Matteo Hospital in Pavia vs. Technogenetics (298.96 KB)
07/12/20 - 10:35
Communication on total amount of voting rights (563.18 KB)
04/12/20 - 16:14
Form 3F (November 2020) (10.2 KB)
01/12/20 - 6:33
DiaSorin received FDA approval for its LIAISON® XL MUREX HIV Ab/Ag assay, completing the Hepatitis and Retrovirus offer in the US market (566.6 KB)
11/11/20 - 12:41
North America growth drives up revenues and profitability in the first 9 months of 2020 (805.25 KB)
26/10/20 - 18:30
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients (414.59 KB)
23/10/20 - 19:41
Conclusion treasury shares buy-back plan (314.28 KB)
23/10/20 - 19:37
Weekly report treasury shares buy-back (436.92 KB)
16/10/20 - 18:28
Weekly report treasury shares buy-back (425.19 KB)
01/10/20 - 7:45
DiaSorin received FDA approval on 6 Hepatitis B tests, completing its Hepatitis offer in the US market (395.31 KB)
01/10/20 - 7:32
DiaSorin’s LIAISON SARS-CoV-2 IgM test receives FDA Emergency Use Authorization for the U.S. market (488.09 KB)
23/09/20 - 7:16
DiaSorin extends its current joint venture with the Chinese Government to open a new manufacturing and research site in China (495.78 KB)
16/09/20 - 14:30
Update Annual Calendar of Corporate Events 2020 (222.26 KB)
16/09/20 - 7:25
DiaSorin Simplexa™ COVID-19 Direct molecular test CE marked for saliva specimens (477.67 KB)
08/09/20 - 7:31
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution (506.16 KB)
07/09/20 - 18:22
FDA approval of Simplexa flu A_B & RSV Direct Gen II Assay (400.26 KB)
06/08/20 - 7:25
DiaSorin announces the launch of its new CE marked LIAISON Testosterone xt test for the dosage of testosterone (391.91 KB)
31/07/20 - 16:04
Weekly report treasury shares buy-back (380.16 KB)
30/07/20 - 13:16
North America business growth drives Group revenues and profitability in H1 2020 (735.54 KB)
24/07/20 - 17:19
Weekly report treasury shares buy-back (363.73 KB)
17/07/20 - 18:19
Weekly report treasury shares buy-back (360.09 KB)
10/07/20 - 18:23
Weekly report treasury shares buy-back (374 KB)
09/07/20 - 7:27
DiaSorin will provide the UK Government with its LIAISON SARS-CoV-2 S1/S2 IgG serology kit for COVID-19 testing to run a national screening study (399.63 KB)
07/07/20 - 7:22
DiaSorin CE marks their new Simplexa Flu A/B & RSV Direct Gen II Assay to run with the Simplexa COVID-19 Direct assay (490.1 KB)
30/06/20 - 7:25
DiaSorin announces the launch of its new LIAISON® SARS-COV-2 IgM test, a new fully automated serology kit available in Europe and in the U.S. to identify the immediate response to SARS-COV-2 in COVID-19 patients (397.37 KB)
19/06/20 - 17:20
Weekly report treasury shares buy-back (399.38 KB)
17/06/20 - 16:09
Start up of the treasury shares buy-back plan (481.28 KB)
12/06/20 - 7:30
DiaSorin has CE marked its molecular's Simplexa™ Congenital CMV Direct Assay (478.6 KB)
10/06/20 - 15:40
Shareholders' Meeting June 10, 2020 (308.25 KB)
03/06/20 - 14:16
The LIAISON® SARS-COV-2 S1/S2 IgG test received the approval for the commercialization in Brazil from ANVISA (397.21 KB)
02/06/20 - 14:58
Communication total amount voting rights (record date) (267.83 KB)
18/05/20 - 11:28
The LIAISON® SARS-COV-2 S1S2 IgG test is the first to receive the approval from Health Canada (308.26 KB)
13/05/20 - 13:15
DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic (741.65 KB)
25/04/20 - 16:49
DiaSorin - FDA EUA and BARDA funding for SARS-CoV-2 IgG (403.66 KB)
17/04/20 - 18:25
DiaSorin has CE marked its SARS-COV-2 IgG serology kit for COVID-19 (464.49 KB)
07/04/20 - 7:14
IgG test to detect immune response to SARS-CoV-2 (394.92 KB)
26/03/20 - 18:14
Update Annual Calendar of Corporate Events 2020 (277.25 KB)
21/03/20 - 20:29
Shareholders' Meeting date change (288.23 KB)
20/03/20 - 7:28
DiaSorin COVID-19 test has received FDA Emergency Use Authorization (397.04 KB)
13/03/20 - 17:16
DiaSorin received BARDA funding to develop a rapid COVID-19 test (403.34 KB)
11/03/20 - 13:43
DiaSorin - Cash flow generation and net profit hit record highs in 2019 (919.6 KB)
10/03/20 - 8:20
DiaSorin - Development of Coronavirus test (404.03 KB)
02/03/20 - 8:04
DiaSorin signs an exclusive licensing agreement for molecular diagnostic POC technology (396.06 KB)
07/02/20 - 8:06
Communication on total amount of voting rights (281.13 KB)
15/01/20 - 16:51